Page last updated: 2024-12-08

isovitexin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4475102
CHEMBL ID1601394
CHEBI ID139454
SCHEMBL ID20870220
MeSH IDM0142440
PubMed CID162350
CHEMBL ID465360
CHEBI ID18330
SCHEMBL ID513620
MeSH IDM0142440

Synonyms (85)

Synonym
LS-14857
NCGC00180782-01
MEGXP0_000100
ACON1_000206
MLS000877022 ,
smr000440604
CHEBI:139454
BRD-A01088251-001-01-5
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
HMS2270H05
FT-0686646
FT-0645081
CHEMBL1601394
6-[6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-2-(4-hydroxyphenyl)-5,7-bis(oxidanyl)chromen-4-one
cid_4475102
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one
bdbm60722
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-(3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl)chromone
sr-01000758946
SR-01000758946-3
SCHEMBL20870220
isovitexin(4)
29702-25-8
6-glucosylapigenin
(1s)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-6-yl]-d-glucitol
CHEBI:18330 ,
beta-d-isovitexin
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one
4h-1-benzopyran-4-one, 6-beta-d-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-
apigenin 6-c-glucoside
38953-85-4
isovitexin ,
6-c-glucosylapigenin
saponaretin
C01714 ,
apigenin-6-c-glucoside
NCGC00163578-01
isovitexin, >=98.0% (hplc)
MLS002473147
MLS000563041
smr001215816
CHEMBL465360
homovitexin
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
flavone, 6-beta-d-glucopyranosyl-4',5,7-trihydroxy-
unii-ktq9r9ms0q
6-beta-d-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
ccris 9341
isoavroside
ktq9r9ms0q ,
apigenin 6-c-beta-glucopyranoside
4h-1-benzopyran-4-one, 6-beta-d-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)- (van)
HMS2268O04
S9035
6-c-.beta.-d-glucopyranosylapigenin
avroside
4h-1-benzopyran-4-one, 6-.beta.-d-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-
isovitexin [who-dd]
CCG-208397
SCHEMBL513620
mfcd00076044
isovitexin with hplc
AC-34970
ethyl6-amino-5-cyano-2-methyl-4-phenyl-4h-pyran-3-carboxylate
flavone, 6-.beta.-d-glucopyranosyl-4',5,7-trihydroxy-
MYXNWGACZJSMBT-VJXVFPJBSA-N
isovitexin, analytical standard
isovitexin, primary pharmaceutical reference standard
bdbm50486938
AKOS032948364
Q3155636
isovitexin with
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)-4h-chromen-4-one
HY-N0773
CS-0009796
HMS3886D14
saponaretin;homovitexin
6-c-beta-d-glucopyranosylapigenin
DTXSID60952152
AS-56231
saponaretin; homovitexin
isovitexin 100 microg/ml in acetonitrile:methanol
6-glucosyl-apigenin
isovitexin (constituent of hawthorn leaf with flower)
(1s)-1,5-anhydro-1-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-6-yl)-d-glucitol

Research Excerpts

Overview

Isovitexin (IVX) is a trihydroxyl flavonoid that is a naturally bioactive ingredient found in various medicinal plants. It has antioxidant, anti‑inflammatory and neuroprotective properties. Isovite X (IVT) is well-known flavone C-glycoside found in many plants.

ExcerptReferenceRelevance
"Isovitexin (IVX) is a trihydroxyl flavonoid that is a naturally bioactive ingredient found in various medicinal plants and has antioxidant, anti‑inflammatory and neuroprotective properties."( Isovitexin restores sevoflurane‑induced cognitive dysfunction by mediating autophagy through activation of the PGC‑1α/FNDC5 signaling pathway.
Chen, Q; Guo, Y; Sun, L; Wu, B, 2022
)
2.89
"Isovitexin (IV) is a flavone that has the potential for anticancer, antioxidant, and anti-inflammatory."( The effect of isovitexin on lipopolysaccharide-induced renal injury and inflammation by induction of protective autophagy.
Chen, JH; Hsu, CC; Lin, HH; Tseng, CY; Yu, PR, 2023
)
1.99
"Isovitexin (ISO) is a glycosylated flavonoid obtained from Asian rice that has been reported to have anti-inflammatory effect. "( Isovitexin prevents DSS-induced colitis through inhibiting inflammation and preserving intestinal barrier integrity through activating AhR.
Li, R; Mu, J; Song, J; Wang, D; Xue, T; Yu, J, 2023
)
3.8
"Isovitexin (IVT) is a promising hepatoprotective agent owing to its efficacy against acute liver injury."( Isovitexin alleviates hepatic fibrosis by regulating miR-21-mediated PI3K/Akt signaling and glutathione metabolic pathway: based on transcriptomics and metabolomics.
Chen, S; Huang, Y; Long, Y; Luo, W; Qiu, Y; Shi, Y; Su, H; Wei, J; Wei, Y; Zhu, W, 2023
)
3.07
"Isovitexin (IVT) is a well-known flavone C-glycoside found in many plants and has attracted wide attention due to its obvious antitumor and antioxidant effects."( Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
Chen, RL; He, JQ; Huang, P; Sun, CH; Wang, Z; Yu, CH; Yu, WY; Zhang, HH, 2021
)
2.79
"Isovitexin (ISO) is a glycosylated flavonoid that exhibits a potential antioxidant activity."( Binding of antioxidant flavone isovitexin to human serum albumin investigated by experimental and computational assays.
Caruso, ÍP; Cornélio, ML; de Souza, FP; Fossey, MA; Vilegas, W, 2014
)
1.41

Effects

Isovitexin (IVX) has anti-inflammatory properties and passes through the blood-brain barrier. The molecular mechanism that modulates IVX-mediated microglial polarization remains unclear.

ExcerptReferenceRelevance
"Isovitexin has an oral bioavailability of 14.58%."( Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide.
Chattopadhyay, N; Chattopadhyay, S; Gayen, JR; Kulkarni, C; Pal, S; Porwal, K; Riyazuddin, M; Sanyal, S; Sharma, S, 2022
)
1.75
"Isovitexin has an oral bioavailability of 14.58%."( Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide.
Chattopadhyay, N; Chattopadhyay, S; Gayen, JR; Kulkarni, C; Pal, S; Porwal, K; Riyazuddin, M; Sanyal, S; Sharma, S, 2022
)
1.75
"Isovitexin (IVX) has anti-inflammatory properties and passes through the blood-brain barrier; however, the molecular mechanism that modulates IVX-mediated microglial polarization remains unclear."( Isovitexin-Mediated Regulation of Microglial Polarization in Lipopolysaccharide-Induced Neuroinflammation via Activation of the CaMKKβ/AMPK-PGC-1α Signaling Axis.
Du, J; Fu, S; He, D; Hu, G; Huang, B; Li, Y; Liu, B; Liu, D; Ran, X, 2019
)
2.68

Toxicity

ExcerptReferenceRelevance
"The acute toxicity study showed that the LD50 of the extract was greater than 5000 mg/kg."( Genotoxicity and acute and subchronic toxicity studies of a standardized methanolic extract of Ficus deltoidea leaves.
Ahamed, MB; Asmawi, MZ; Farsi, E; Hor, SY; Ismail, Z; Shafaei, A; Yam, MF, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
") Merr has been established, based on analysis of high-performance liquid chromatography fingerprint combined with the similarity analysis (SA), hierarchical cluster analysis (HCA), principal component analysis (PCA), discriminant analysis (DA) and the quantitative analysis multi-components by single marker (QAMS) method."( Quantitative and Chemical Fingerprint Analysis of Desmodium styracifolium by High-Performance Liquid Chromatography Combined with Chemometrics.
Chen, L; Cheng, X; Tang, X; Yang, Q, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Isovitexin has an oral bioavailability of 14."( Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide.
Chattopadhyay, N; Chattopadhyay, S; Gayen, JR; Kulkarni, C; Pal, S; Porwal, K; Riyazuddin, M; Sanyal, S; Sharma, S, 2022
)
1.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.2.1.20 (alpha-glucosidase) inhibitorAn EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
C-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
C-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
trihydroxyflavoneAny hydroxyflavone carrying three hydroxy groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency9.83440.003245.467312,589.2998AID2517; AID2572
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency42.80000.125919.1169125.8920AID2549; AID504841
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
WRNHomo sapiens (human)Potency50.11870.168331.2583100.0000AID651768
ATAD5 protein, partialHomo sapiens (human)Potency20.72440.004110.890331.5287AID504466; AID504467
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978
thioredoxin glutathione reductaseSchistosoma mansoniPotency70.79460.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.54810.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency35.48130.036619.637650.1187AID2100
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency8.91250.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency50.11870.133725.412989.1251AID588795
snurportin-1Homo sapiens (human)Potency112.20205.804836.130665.1308AID540263
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency63.09570.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency21.94330.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency34.53440.050127.073689.1251AID588590; AID720496
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency15.84890.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency39.81070.031622.3146100.0000AID588579
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency100.00000.00419.962528.1838AID2675
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency12.58930.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency12.58930.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency12.58930.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency12.58930.01418.602439.8107AID2572
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency79.43283.981146.7448112.2020AID720708
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency19.95260.07578.474229.0628AID602233
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency19.95260.004023.8416100.0000AID485290
67.9K proteinVaccinia virusPotency1.00000.00018.4406100.0000AID720579
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
Guanine nucleotide-binding protein GHomo sapiens (human)Potency4.46681.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
integrase, partialHuman immunodeficiency virus 1IC50 (µMol)4.28800.07953.52039.9390AID1053171; AID1053172
lens epithelium-derived growth factor p75Homo sapiens (human)IC50 (µMol)4.28800.07953.52039.9390AID1053171; AID1053172
VifHuman immunodeficiency virus 1IC50 (µMol)7.05000.270034.0015100.0000AID1117319
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)7.05000.270026.3638100.0000AID1117319
large T antigenBetapolyomavirus macacaeIC50 (µMol)21.43000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neurotensin receptor type 1Homo sapiens (human)EC50 (µMol)2.71002.710010.320019.6000AID504549
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID721013Induction of apoptosis in human HL60 cells assessed as DNA fragmentation at 12.5 uM after 24 hrs by agarose gel electrophoresis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID551462Antioxidant activity assessed as copper ion radical scavenging activity at 2 uM2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Antioxidant activity of a new C-glycosylflavone from the leaves of Ficus microcarpa.
AID721014Cytotoxicity against human HF19 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1884963Inhibition of Staphylococcus aureus USA300 Sortase A protease expressed in Escherichia coli BL21 expression system using Abz-LPATG-Dap(Dnp)-NH2 as substrate incubated for 30 mins by FRET assay2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Small Carbohydrate Derivatives as Potent Antibiofilm Agents.
AID403582Inhibition of thrombin-induced platelet aggregation in rabbit plasma at 300 uM preincubated 3 mins before addition of thrombin by turbidimetric method1997Journal of natural products, Aug, Volume: 60, Issue:8
A new flavone C-glycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis.
AID721018Cytotoxicity against human KATO III cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID721021Cytotoxicity against human U937 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID403591Inhibition of collagen-induced platelet aggregation in rabbit plasma at 300 uM preincubated 3 mins before addition of thrombin by turbidimetric method1997Journal of natural products, Aug, Volume: 60, Issue:8
A new flavone C-glycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis.
AID403584Inhibition of arachidonic acid-induced platelet aggregation in rabbit plasma at 300 uM preincubated 3 mins before addition of thrombin by turbidimetric method1997Journal of natural products, Aug, Volume: 60, Issue:8
A new flavone C-glycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1236855Retention time of the compound by HPLC-SPE-NMR analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Acylated glucosylflavones as α-glucosidase inhibitors from Tinospora crispa leaf.
AID551463Metal chelating activity of the compound at 1 to 2 uM2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Antioxidant activity of a new C-glycosylflavone from the leaves of Ficus microcarpa.
AID721016Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID403594Inhibition of platelet activating factor-induced platelet aggregation in rabbit plasma at 300 uM preincubated 3 mins before addition of thrombin by turbidimetric method1997Journal of natural products, Aug, Volume: 60, Issue:8
A new flavone C-glycoside and antiplatelet and vasorelaxing flavones from Gentiana arisanensis.
AID721019Cytotoxicity against human Jurkat cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID1236853Inhibition of Bacillus stearothermophilus alpha-glucosidase2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Acylated glucosylflavones as α-glucosidase inhibitors from Tinospora crispa leaf.
AID1884964Antibiofilm activity against Staphylococcus aureus USA300 assessed as inhibition of biofilm formation at 256 ug/ml measured after 24 hrs by crystal violet staining based assay relative to control2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Small Carbohydrate Derivatives as Potent Antibiofilm Agents.
AID721015Cytotoxicity against human NB1RGB cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID721022Cytotoxicity against human HL60 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID721017Cytotoxicity against human HCT15 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID721020Cytotoxicity against human THP1 cells assessed as cell viability after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Antiproliferative and apoptotic effects of compounds from the flower of Mammea siamensis (Miq.) T. Anders. on human cancer cell lines.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.85)18.7374
1990's2 (1.71)18.2507
2000's24 (20.51)29.6817
2010's64 (54.70)24.3611
2020's26 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.86 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews5 (4.07%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other118 (95.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]